Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Instituto Bernabeu | OTHER |
Not provided
Not provided
Not provided
Not provided
The investigators aim to examine the endometrium with state of the art sequencing techniques to investigate the endometrial microbiota. The endometrial microbiota has been perceived to be sterile, however, this seems incorrect from recent studies. Thus, the primary outcome is to compare the rate of ascending infection from the vagina to the endometrium and to investigate which bacteria are capable of inhabiting these environments in healthy oocyte donors. These results will be compared to equivalent samples of IVF patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Oocyte donors | Healthy Oocyte donors fulfilling the criteria for oocyte donation are eligible. Patients may not have received any antibiotics or vaginal products (other than for menstrual hygiene - such as tampons) for the last 1 month. Informed consent is mandatory. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Rate of ascending infection/sharing of bacteria in the genital tract | vaginal, cervical and endometrial samples will be compared at the time of oocyte retrieval. | This outcome data is measured at the 1 day of oocyte retrieval. |
| Measure | Description | Time Frame |
|---|---|---|
| Next generation sequencing techniques and qPCR will be used to assess the microbiota.I.e. measure of relative abundances and absolute abundances | qPCR to assess the microbiota. I.e. a quantitative measure Copies/mL. 16S V4 to investigate relative abundances | This outcome data is measured at the 1 day of oocyte retrieval. |
Not provided
Inclusion Criteria:
Oocyte donors meeting local criteria for donation. Written informed consent. Regular cycle
Exclusion Criteria:
Antibiotics within 1 month Vaginal products other than for menstrual hygiene within 1 month Uterine malformations(Septum, polyps, adenomyosis, fibroids) HIV, Hepatitis B or C positivity. HPV CIN 2 or higher. Chlamydia trachomatis positivity.
Any uncontrolled concomitant disease (e.g. uncontrolled diabetes, uncontrolled hypertension etc.)
Not provided
Not provided
Healthy oocyte donors
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Instituto Bernabeu | Alicante | Spain |
WE plan to share all information allowed as per national law.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016585 | Vaginosis, Bacterial |
| ID | Term |
|---|---|
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D014627 | Vaginitis |
Not provided
Not provided
Not provided
Not provided
Not provided
Vaginal, Cervical and endometrial samples taken with the Eswab (Copan), eNAT (Copan) and Tao brush (Cook medical). Although there will be Human DNA in samples, we aim to isolate bacterial DNA for further analysis. No analyses are planned on Human DNA.
| D014623 |
| Vaginal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |